Neurofibromatosis type 2–associated meningiomas: an international multicenter study of outcomes after Gamma Knife stereotactic radiosurgery
Authors:
Open Access
- 1 January 2022
- journal article
- research article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 136 (1) , 109-114
Abstract
OBJECTIVE: The management of neurofibromatosis type 2 (NF2)–associated meningiomas is challenging. The role of Gamma Knife radiosurgery (GKRS) in the treatment of these tumors remains to be fully defined. In this study, the authors aimed to examine the role of GKRS in the treatment of NF2-associated meningiomas and to evaluate the outcomes and complications after treatment. METHODS: Seven international medical centers contributed data for this retrospective cohort. Tumor progression was defined as a ≥ 20% increase from the baseline value. The clinical features, treatment details, outcomes, and complications were studied. The median follow-up was 8.5 years (range 0.6–25.5 years) from the time of initial GKRS. Shared frailty Cox regression was used for analysis. RESULTS: A total of 204 meningiomas in 39 patients treated with GKRS were analyzed. Cox regression analysis showed that increasing the maximum dose (p = 0.02; HR 12.2, 95% CI 1.287–116.7) and a lower number of meningiomas at presentation (p = 0.03; HR 0.9, 95% CI 0.821–0.990) were predictive of better tumor control in both univariable and multivariable settings. Age at onset, sex, margin dose, location, and presence of neurological deficit were not predictive of tumor progression. The cumulative 10-year progression-free survival was 94.8%. Radiation-induced adverse effects were noted in 4 patients (10%); these were transient and managed medically. No post-GKRS malignant transformation was noted in 287 person-years of follow-up. CONCLUSIONS: GKRS achieved effective tumor control with a low and generally acceptable rate of complications in NF2-associated meningiomas. There did not appear to be an appreciable risk of post–GKRS-induced malignancy in patients with NF2-treated meningiomas.Keywords
This publication has 17 references indexed in Scilit:
- 3D Volumetric Measurement of Neurofibromatosis Type 2-Associated Meningiomas: Association Between Tumor Location and Growth RateWorld Neurosurgery, 2015
- The role of the concept of biologically effective dose (BED) in treatment planning in radiosurgeryPhysica Medica, 2015
- Gamma Knife radiosurgery for meningiomas in patients with neurofibromatosis Type 2Journal of Neurosurgery, 2015
- The Importance of the Conformality, Heterogeneity, and Gradient Indices in Evaluating Gamma Knife Radiosurgery Treatment Plans for Intracranial MeningiomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular featuresNeuro-Oncology, 2012
- Ring chromosome 22 and neurofibromatosis type II: proof of two‐hit model for the loss of the NF2 gene in the development of meningiomaClinical Genetics, 2010
- Mutational spectrum of theNF2gene: a meta-analysis of 12 years of research and diagnostic laboratory findingsHuman Mutation, 2007
- Predictors of the Risk of Mortality in Neurofibromatosis 2The American Journal of Human Genetics, 2002
- Neurofibromatosis 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneityAmerican Journal of Medical Genetics, 1994
- Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2Nature, 1993